nicopass fresh mint 1.5 base milligrams lozenges
pierre fabre medicament - nicotine resinate - lozenges - 1.5 base milligrams
nicopass fresh mint 2.5 milligram lozenges
pierre fabre medicament - nicotine - lozenges - 2.5 milligram
nicopass liquorice mint 1.5 base milligrams lozenges
pierre fabre medicament - nicotine resinate - lozenges - 1.5 base milligrams
nicopass liquorice mint 2.5 milligram lozenges
pierre fabre medicament - nicotine - lozenges - 2.5 milligram
pectodrill for chesty coughs 250/5 mg/ml oral solution
pierre fabre medicament - carbocisteine - oral solution - 250/5 mg/ml
topaal chewable tablets 30/40/200/ milligram tablets chewable
pierre fabre medicament - aluminium hydroxide gel, dried magnesium carbonate light alginic acid silica colloidal hydrated - tablets chewable - 30/40/200/ milligram
tussidrill sugar-free for dry coughs 15mg/5ml mg/ml oral solution
pierre fabre medicament - dextromethorphan hydrobromide - oral solution - 15mg/5ml mg/ml
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastic agents - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy
mektovi
pierre fabre medicament - binimetinib - melanoma - antineoplastic agents - binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.
nerlynx
pierre fabre medicament - neratinib - breast neoplasms - antineoplastic agents - nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive her2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy.